Details for Patent: 6,187,791

Scope and Claims Analysis for US Patent 6,187,791 (Terfenadine-Cardiac Liability Avoidance; Histamine-Mediated Disease Treatment)

US Patent 6,187,791 is drafted as a method-of-treatment patent focused on preventing terfenadine-associated cardiac risk (QT prolongation and ventricular tachycardia) while delivering antihistaminic efficacy. The claim set is anchored to a specific chemical genus (substituted carboxylic acids with defined ring substituents and optional stereochemistry) and includes an explicit dependent set specifying particular molecules, plus a separate method claim that uses “racemic terfenadine carboxylate.”

What is the claimed invention in one line?

A method for treating histamine-mediated conditions by administering specified carboxylic-acid compounds (including defined hydroxy/alkyl/carboxylate substitution patterns and enantiomers) or racemic terfenadine carboxylate, expressly in patients at risk of terfenadine-associated arrhythmias.

What patents protect methods to avoid terfenadine cardiac arrhythmias (QT prolongation) with antihistamines?

Core claim theme: antihistaminic effect in QT-prolongation susceptible patients

The patent targets a known liabilities gap in first-generation “H1” antihistamines where terfenadine’s exposure (and metabolic disruption) correlates with ventricular arrhythmias. The language in claims 1 and 5 makes “susceptibility to cardiac events associated with terfenadine” an express treatment qualifier. That structure matters for validity and infringement because it limits the method to a patient population and a clinical intent tied to terfenadine risk.

Two functional claim buckets

1. Genus method claims (claims 1 and 9):
   Treat a histaminic-mediated condition with a compound of a defined formula (including salts and enantiomers), with the patient being one susceptible to terfenadine-associated cardiac events / QT prolongation.

2. Specific compound dependent claims (claims 2–4):
   The method of claim 1 is limited to particular stereochemical embodiments:

   • claim 2: a defined compound (structure named in the claim)
   • claim 3: (R) enantiomer
   • claim 4: (S) enantiomer

3. Separate racemic terfenadine carboxylate use (claims 5–8):
   Treat histamine-mediated disease while avoiding concomitant terfenadine arrhythmia liability by giving racemic terfenadine carboxylate (and salts) with specified dosing ranges in dependent claims.

What is the scope of claim 1’s chemical formula genus (R1/R2/A/B/n/R3) and how broad is it?

Claim 1 scope summary

Claim 1 covers a method using an “effective antihistaminic amount” of a compound defined by the formula (not fully rendered in your prompt but partially specified via variable definitions). The variable definitions provided are:

• R1: hydrogen or hydroxy
• R2: hydrogen
• or R1 and R2 taken together form a second bond between the carbon atoms bearing R1 and R2 (ring-closure style substitution option)
• n: integer 1 to 5
• R3: —COOH or —COOalkyl where alkyl is 1 to 6 carbons, straight or branched
• A and B: hydrogen or hydroxy, with the proviso: at least one of A or B is hydrogen
• Optional forms: pharmaceutically acceptable salts and individual enantiomers

Practical breadth drivers

• Enantiomers are explicitly included. That increases scope to separate stereochemical products and also complicates design-around, because even single-enantiomer versions can fall within the “individual enantiomers” language if they match the formula.
• Salt inclusion expands infringement surface to salt forms (e.g., sodium/potassium, etc.) when the active moiety remains the same.
• Carboxylic acid vs alkyl ester at R3 (“—COOH or —COOalkyl”) increases chemical diversity. Even though esters can change pharmacokinetics, the claim reads on both acid and low-carbon esters (C1–C6, linear/branched).
• A/B hydroxy constraint (“at least one is hydrogen”) removes fully di-hydroxy at both positions, but still permits:
  • A = H, B = hydroxy
  • A = hydroxy, B = H
  • A = H, B = H
    That is still multiple substitution patterns.

Breadth limitation: R2 fixed at hydrogen except for the “R1-R2 taken together form a second bond” option

R2 is stated as hydrogen in the main branch, so most of the genus is anchored to monohydroxy (via R1) rather than multi-substitution at R2.

n = 1–5 adds homolog range

An integer n from 1 to 5 generally widens the claim to multiple chain lengths or ring sizes depending on where n sits in the structure. That typically creates a moderate-to-high genus expansion.

How do dependent claims 2–4 narrow claim 1 to specific compounds (including enantiomers)?

Claim 2 recites a specific compound by name (the prompt includes the structure as:
“4-[1-hydroxy-4-[4-(hydroxydiphenymethyl)-1-piperidinyl]butyl]-α,α-dimethyl benzeneacetic acid.”)

Claim 3 and claim 4 then narrow to:

• (R) enantiomer (claim 3)
• (S) enantiomer (claim 4)

Scope impact

• These dependent claims create a direct infringement path for manufacturers selling the single enantiomers (if the stereocenters align with the claim’s (R)/(S) definitions).
• They also strengthen enforceability because even if the genus is contested as invalid/indefinite/too broad, the specific disclosed compounds can still be asserted via the narrowed claims.

What is the scope of claim 5’s “racemic terfenadine carboxylate” method and why is it separate from claim 1?

What claim 5 covers

Claim 5 adds an explicit alternative compound set:

• “racemic terfenadine carboxylate” or a pharmaceutically acceptable salt.

It is tied to:

• treating histamine-mediated disease in a human
• while avoiding the concomitant liability of cardiac arrhythmias associated with administration of terfenadine

Relationship to claim 1

Even though claim 1 is also about avoiding terfenadine cardiac events (patient qualifier) and uses a defined formula genus, claim 5:

• identifies a commercially recognizable molecule class (“terfenadine carboxylate”)
• uses “racemic” (a specific stereochemical statement)

So claim 5 is effectively a more explicit, litigation-friendly landing spot for products that use terfenadine carboxylate as the active, regardless of whether the broader genus is argued in detail.

What dosing ranges are claimed for racemic terfenadine carboxylate (claims 6–7)?

• Claim 6: about 20 mg to about 800 mg per day
• Claim 7: about 40 mg to about 360 mg per day

Scope impact

These ranges:

• can be used to target label-compliant or study dosing regimens
• provide a numerical infringement handle even when the factfinder disputes “effective antihistaminic amount” under claim 1

For generic or reformulation developers, these ranges matter because:

• If the intended dosing stays outside both the broad and narrow ranges, the method claims may be harder to assert.
• If clinical trials or real-world dosing fall within the ranges, exposure increases.

What does claim 8 add about formulation or administration (carriers)?

Claim 8 requires:

• the racemic terfenadine carboxylate or pharmaceutically acceptable salt to be administered together with a pharmaceutically acceptable carrier.

Scope impact

This is a conventional carrier language. It typically does not restrict to a specific dosage form. In enforcement terms, it usually reads on tablets, capsules, solutions, suspensions, and other standard presentations, assuming the compound is administered with conventional excipients.

How does claim 9 differ from claim 1 (QT prolongation / ventricular tachycardia language)?

Claim 9 is drafted as another “improvement” statement:

• “In a method of providing an antihistaminic effect in a patient susceptible to QT prolongation and/or ventricular tachycardia when using terfenadine…”

Then it requires:

• administering an “effective amount” of the same genus formula compounds as claim 1 (including salts and enantiomers).

Scope impact

Claim 9 focuses on QT prolongation and ventricular tachycardia explicitly, which may allow:

• separate litigation theories depending on the clinical evidence available about cardiac risk
• alignment with mechanistic monitoring outcomes in trials (ECG endpoints)

Claim 1 is broader in that it frames “possible cardiac events associated with administration of terfenadine,” while claim 9 is more specific mechanistically.

How strong is the patent estate for US 6,187,791 and what claim elements drive enforceability?

Based on the claims provided, the key enforceability drivers are:

1. Patient population qualifier tied to terfenadine risk
   This links the method to a clinical context. It can be challenged as being non-structural or as an intended-use limitation, but it also provides a clear factual hook.

2. Compound definition with variable constraints plus salts/enantiomers
   If the formula is well-supported in the specification, it strengthens claim construction. If not, the genus could be attacked, but dependent claims 2–4 and claim 5 can still anchor enforcement.

3. Explicit enumerated compounds and enantiomers
   Claims 2–4 and the stereochemical statements reduce the dependence on broad genus interpretation.

4. Numeric dosing ranges
   Claims 6–7 add a concrete infringement trigger.

What this means in business terms: the patent is structured to support multiple infringement theories:

• product-based (specific compounds within claim 2–4 or terfenadine carboxylate in claim 5)
• patient-based (QT/ventricular tachycardia susceptibility)
• regimen-based (dosing range in claims 6–7)
• administration-based (carrier requirement in claim 8)

What generic entry risks exist for products that treat histamine-mediated disease in QT-prolongation susceptible patients?

Risk vector A: method claims asserted against prescribing physicians

Even if generics market the chemical, method-of-treatment claims can be implicated through labeled or practiced regimens. For this patent, the “while avoiding terfenadine arrhythmias” language and QT/v-tachy qualifier increases the importance of:

• clinical indications
• patient screening language in prescribing information
• evidence of intended use in trials

Risk vector B: dosing-range infringement

If an accused regimen uses racemic terfenadine carboxylate at 20–800 mg/day or especially 40–360 mg/day, claims 6–7 provide a straightforward infringement argument.

Risk vector C: formulation and carrier

Carrier language in claim 8 is unlikely to provide a strong design-around. Most solid and liquid dosage forms will satisfy “pharmaceutically acceptable carrier.”

How does US 6,187,791 likely compare with other terfenadine-metabolism liability patents?

Without additional bibliographic data (continuations, related families, and specification-defined compound sets), the only defensible comparison is structural:

• This patent is not drafted as “avoid arrhythmia by not using terfenadine,” but instead as “avoid concomitant liability while treating with terfenadine-derived carboxylate class compounds or related formula-defined compounds.”
• That differentiates it from patents that only cover metabolism inhibition, formulation-matrix stabilization to prevent peak exposure, or general QT-risk warnings.

In litigation strategy terms, this type of patent is commonly asserted in cases where a competitor attempts to market a terfenadine liability-avoiding metabolite or related acid form for H1 indication.

What Orange Book status or FDA exclusivity governs US 6,187,791?

No Orange Book or FDA regulatory status can be determined from the provided content. Without the application/bibliographic bridge (listed drug, NDA/ANDA/BLA, approval dates, Orange Book entries, and listed patents), the patent’s regulatory linkage cannot be stated.

Key Takeaways

• US 6,187,791 is a method-of-treatment patent centered on antihistaminic therapy that avoids terfenadine-associated cardiac risk, with explicit focus on QT prolongation and ventricular tachycardia susceptibility.
• Claim scope is driven by a genus defined by variable substituents (R1 hydrogen/hydroxy; R2 hydrogen with a bond-closure option; n = 1–5; R3 acid or low-carbon alkyl ester; A/B hydrogen/hydroxy with “at least one hydrogen”), plus salts and enantiomers.
• Dependent claims 2–4 narrow to a named compound and its (R) and (S) enantiomers, enabling targeted enforcement.
• Claims 5–8 provide a clearer product-based anchor: racemic terfenadine carboxylate (and salts) with daily dosing ranges (20–800 mg/day; 40–360 mg/day) and conventional carrier language.
• Claim 9 creates an additional “improvement” theory explicitly framed by QT prolongation and/or ventricular tachycardia in terfenadine-susceptible patients.

FAQs

1. Does claim 1 cover both carboxylic acids and ester prodrugs?
   Yes. Claim 1 includes R3 as “—COOH or —COOalkyl” with alkyl of 1–6 carbons.

2. Are single-enantiomer products within the patent scope?
   Yes. Claim 1 expressly includes “individual enantiomers,” and claims 3–4 separately cover the (R) and (S) forms of the named compound.

3. What is the narrowest dosing limit for racemic terfenadine carboxylate in the patent?
   Claim 7: about 40 mg to about 360 mg per day.

4. Can a competitor avoid infringement by changing the carrier/excipient?
   Claim 8 requires administration “with a pharmaceutically acceptable carrier,” which typically reads broadly across standard formulation types.

5. Is QT prolongation susceptibility a required element for claim 9?
   Yes. Claim 9 explicitly limits the patient to those susceptible to QT prolongation and/or ventricular tachycardia when using terfenadine.

References

1. United States Patent 6,187,791. (as provided in user prompt; claim text analyzed).